The serum concentration of the receptor activator of nuclear factor-kB ligand (RANKL), osteoprotegerin (OPG) and lipids profile in children with nephrotic syndrome

被引：0
|
作者：
Panczyk-Tomaszewska, M. [1 ]
Ziolkowska, H. [1 ]
Adamczuk, D. [1 ]
Gorska, E. [2 ]
Stelmaszczyk-Emmel, A. [2 ]
Roszkowska-Blaim, M. [1 ]
机构：
[1] Med Univ Warsaw, Dept Pediat & Nephrol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Lab Diagnost & Clin lmuunol Dev Age, Warsaw, Poland
来源：
BONE | 2009年 / 45卷
关键词：
D O I：
10.1016/j.bone.2009.04.121
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [31] The Effect of Osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) on Aortic Valve Calcified
    Luo, Wei
    Wang, Jing
    Yang, Xia
    Li, Junshan
    Song, Yanqiu
    Cong, Hongliang
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2024, 54 (05): : 633 - 642
  • [32] Serum levels of receptor activator of nuclear factor kB ligand (RANKL) in healthy women and men
    Kerschan-Schindl, K.
    Wendlova, J.
    Kudlacek, S.
    Gleiss, A.
    Woloszcuk, W.
    Pietschmann, P.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S340 - S340
  • [33] ROLE OF RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND (RANKL) AND OSTEOPROTEGERIN (OPG) IN PERIODONTAL BONE DESTRUCTION: A REVIEW
    Moon, Ninad
    Khan, Mohd. Inayatulla
    Moon, Archana
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2014, 3 (18): : 4781 - 4785
  • [34] Serum Osteoprotegerin (OPG) in Children with Primary Nephrotic Syndrome
    Mohamed, Gamal B.
    Abdel-Latif, Esmat A.
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2011, 22 (05) : 955 - 962
  • [35] Serum Osteoprotegrin (OPG) and Receptor Activator of Nuclear Factor κB (RANKL) in Healthy Children and Adolescents
    Wasilewska, A.
    Rybi-Szuminska, A. A.
    Zoch-Zwierz, W.
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2009, 22 (12): : 1099 - 1104
  • [36] Serum osteoprotegerin and receptor activator nuclear factor ligand (RANKL) in Paget's disease of bone.
    Alvarez, L
    Guañabens, N
    Peris, P
    Ros, I
    Ferró, T
    Pons, F
    Filella, X
    Monegal, A
    Muñoz-Gomez, J
    Ballesta, AM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S380 - S380
  • [37] Ovariectomy increases vascular calcification via the receptor activator of nuclear factor-kB ligand/osteoprotegerin cytokine signaling pathway
    Choi, Brian G.
    Vilahur, Gemma
    Cardoso, Luis
    Fritton, J. C.
    Zafar, M. U.
    Yadegar, Daniel
    Ibanez, Borja
    Viles-Gonzalez, Juan F.
    Schaffler, Mitchell B.
    Fuster, Valentin
    Badimon, Juan J.
    CIRCULATION, 2006, 114 (18) : 76 - 76
  • [38] Relationships Between Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor κB Ligand (RANKL), and Growth Hormone (GH) Secretory Status in Short Children
    Flint, Janna
    Wu, Shufang
    Shott, Susan
    Suarez, Elizabeth
    De Luca, Francesco
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2009, 22 (12): : 1105 - 1112
  • [39] Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-KB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease
    Ugay Ludmila
    Kochetkova Evgenia
    Nevzorova Vera
    Maistrovskaia Yuliya
    中华医学杂志英文版, 2016, 129 (14) : 1696 - 1703
  • [40] Emerging roles of Interleukin-34 together with receptor activator of nuclear factor-kB ligand and osteoprotegerin levels in periodontal disease
    Dogan, Seyma Bozkurt
    Dede, Figen Ongoz
    Balli, Umut
    Sertoglu, Erdim
    CYTOKINE, 2021, 144
12345